Alterity Therapeutics (ATHE) announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHE:
- Alterity Therapeutics Completes Key Phase 2 Trial for MSA Treatment
- Alterity Therapeutics Reports Progress and Financial Results
- Buy Rating for Alterity Therapeutics: Strong Financial Position and Promising Clinical Results
- Alterity Therapeutics Announces Change in Substantial Holding
- Alterity Therapeutics Expands Capital with New Securities Quotation